Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
CORRESP

CORRESP

 View HTML
0001104659-15-030564.pdf
0001104659-15-030564.rtf
0001104659-15-030564.xls
S-1/A

Amended Registration statement for face-amount certificate companies

 View HTML
0001047469-15-003668.pdf
0001047469-15-003668.rtf
0001047469-15-003668.xls
S-1/A

Amended Registration statement for face-amount certificate companies

 View HTML
0001047469-15-003351.pdf
0001047469-15-003351.rtf
0001047469-15-003351.xls
CORRESP

CORRESP

 View HTML
0001104659-15-026544.pdf
0001104659-15-026544.rtf
0001104659-15-026544.xls
UPLOAD

UPLOAD

 View HTML
0000000000-15-020307.pdf
S-1

Registration statement for face-amount certificate companies

 View HTML
0001047469-15-002608.pdf
0001047469-15-002608.rtf
0001047469-15-002608.xls
CORRESP

CORRESP

 View HTML
0001104659-15-021789.pdf
0001104659-15-021789.rtf
0001104659-15-021789.xls
UPLOAD

UPLOAD

 View HTML
0000000000-15-016713.pdf
DRS/A

mendment to a previously filed DRS

 View HTML
0000912057-15-000057.pdf
0000912057-15-000057.rtf
0000912057-15-000057.xls
DRS

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

 View HTML
0000912057-15-000045.pdf
0000912057-15-000045.rtf
0000912057-15-000045.xls